A wholly owned subsidiary of Cytometric Therapeutics, WCG provides the functional data that informs treatment selection and clinical development.

Functional testing in a three-dimensional tumor environment

CytoVantage 3D measures how living tumor cells respond to cancer therapies within intact cell clusters. This approach preserves tumor biology and enables direct observation of treatment response.

Why ​CytoVantage 3D is Different

Direct Functional Evidence

Measures real tumor response, including cell deat​​h and resistance.

Combination Insight

Evaluates both single agents and drug combinations.

Clear Response Mapping

Ranks therapies based on observed activity.

Adaptive Over Time

Supports repeat testing as disease evolves.

How ​CytoVantage 3D™ Works

CytoVantage 3D integrates cell biology, quantitative cytometry, and analytical modeling to generate a functional profile of an individual patient’s tumor.

    1. Cell Preparation A viable tumor specimen is processed to preserve representative cancer cell populations.

    2. Therapeutic Challenge Cells are exposed to a structured panel of cancer therapies and clinically relevant drug combinations.

    3. Cytometric Analysis Multiparametric assays measure cellular response across key biological pathways.

    4. Response Profiling Results are integrated into a ranked response profile that identifies therapies demonstrating the strongest activity and highlights potential resistance.

Del​iverables
  • Ranked list of therapies and combinations by functional activity
  • Visual response curves and effect categories (active / limited / resistant)
  • Method notes and interpretation guidance
Turnaround & Logistics
  • Requires a fresh, viable specimen with adequate cellularity
  • Testing panel tailored to clinical context and prior therapies
  • Results delivered in a clear, clinician‑readable report

CytoVantage 3D Clinical Value

For Physicians

  • Evidence‑based support for regimen selection in complex or refractory cases
  • Clarity on non‑responsive options to reduce unnecessary toxicity
  • Signals for combination strategies and sequencing
  • Framework to reassess when disease biology shifts

For Patients & Families

  • Personalized insight grounded in the behavior of your own cancer cells
  • Fewer trial‑and‑error cycles and reduced exposure to ineffective drug
  • Transparent reports that your care team can discuss with you

Frequently Asked Questions

Is CytoVantage 3D the same as genetic testing?

No. Genetic and molecular tests identify mutations that may suggest sensitivity or resistance to treatment. WCG Precision Therapy measures functional response directly by observing how living tumor cells react to therapies. The two approaches can be complementary.

Can every patient sample be tested?

Testing requires a fresh, viable specimen with adequate cellularity. Yield and tumor heterogeneity may affect feasibility or scope.

Are all drugs and combinations included?

Panels reflect clinical context and practicality. Not every agent can be tested, and clinical judgment remains essential.

Does CytoVantage 3D™ replace oncologist expertise?

No. ​CytoVantage 3D is a decision‑support tool. Results are interpreted by clinicians within each patient’s broader medical picture.